Back

Metastatic organotropism in small cell lung cancer

Krishnamurthy, M.; Dhall, A.; Schultz, C. W.; Baird, M. A.; Desai, P.; Odell, J.; Sahoo, S.; Takahashi, N.; Nirula, M.; Zhuang, S.; Huang, Y.; Schroeder, B.; Zhang, Y.; Thomas, M. S.; Redon, C.; Robinson, C.; Thang, L.; Ileva, L.; Patel, N. L.; Kalen, J. D.; Varlet, A.-A.; Zuela-Sopilniak, N.; Jha, A.; Wangsa, D.; Butcher, D.; Morgan, T.; Afzal, A. N.; Chari, R.; Baktiar, K.; Kumar, S.; Pongor, L.; Difilippantonio, S.; Aladjem, M. I.; Pommier, Y.; Jolly, M. K.; Lammerding, J.; Sharma, A. K.; Thomas, A.

2024-10-08 cancer biology
10.1101/2024.10.07.617066 bioRxiv
Show abstract

Metastasis is the leading cause of cancer-related deaths, yet its regulatory mechanisms are not fully understood. Small-cell lung cancer (SCLC) is the most metastatic form of lung cancer, with most patients presenting with widespread disease, making it an ideal model for studying metastasis. However, the lack of suitable preclinical models has limited such studies. We utilized rapid autopsy-derived tumors to develop xenograft models that mimic key features of SCLC, including histopathology, rapid and widespread development of metastasis to the liver, brain, adrenal, bone marrow, and kidneys within weeks, and response to chemotherapy. By integrating in vivo lineage selection with comprehensive bulk and single cell multiomic profiling of transcriptomes and chromatin accessibility, we identified critical cellular programs driving metastatic organotropism to the liver and brain, the most common sites of SCLC metastasis. Our findings reveal the key role of nuclear-cytoskeletal interactions in SCLC liver metastasis. Specifically, the loss of the nuclear envelope protein lamin A/C, encoded by the LMNA gene, increased nuclear deformability and significantly increased the incidence of liver metastasis. Human liver metastases exhibited reduced LMNA expression compared to other metastatic sites, correlating with poorer patient outcomes and increased mortality. This study introduces novel preclinical models for SCLC metastasis and highlights pathways critical for organ-specific metastasis, offering new avenues for the development of targeted therapies to prevent or treat metastatic disease.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancer Letters
35 papers in training set
Top 0.1%
15.0%
2
eLife
5828 papers in training set
Top 17%
6.7%
3
Molecular Cancer Research
49 papers in training set
Top 0.1%
5.1%
4
Cancers
213 papers in training set
Top 1%
4.8%
5
Frontiers in Oncology
103 papers in training set
Top 0.7%
4.8%
6
Oncogene
85 papers in training set
Top 0.4%
4.3%
7
Nature Communications
5641 papers in training set
Top 32%
4.0%
8
Genome Medicine
183 papers in training set
Top 1%
3.2%
9
Cancer Research
130 papers in training set
Top 1%
3.2%
50% of probability mass above
10
Cancer Research Communications
51 papers in training set
Top 0.6%
2.4%
11
JCI Insight
277 papers in training set
Top 3%
2.1%
12
Communications Biology
993 papers in training set
Top 12%
2.0%
13
BMC Biology
265 papers in training set
Top 2%
1.7%
14
Molecular Cancer
16 papers in training set
Top 0.1%
1.7%
15
PLOS Genetics
862 papers in training set
Top 7%
1.7%
16
Acta Neuropathologica Communications
89 papers in training set
Top 1%
1.7%
17
PLOS ONE
5266 papers in training set
Top 48%
1.7%
18
Cells
249 papers in training set
Top 3%
1.7%
19
Cell Reports
1498 papers in training set
Top 21%
1.4%
20
Translational Oncology
21 papers in training set
Top 0.5%
1.4%
21
Journal of Experimental Medicine
119 papers in training set
Top 2%
1.3%
22
iScience
1154 papers in training set
Top 23%
1.3%
23
Molecular Oncology
55 papers in training set
Top 1%
1.1%
24
Cancer Discovery
66 papers in training set
Top 1%
1.1%
25
Journal of Clinical Investigation
179 papers in training set
Top 4%
1.1%
26
Science Advances
1243 papers in training set
Top 25%
1.1%
27
Scientific Reports
3612 papers in training set
Top 69%
1.0%
28
eBioMedicine
183 papers in training set
Top 5%
1.0%
29
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.7%
0.8%
30
Molecular Cancer Therapeutics
40 papers in training set
Top 0.9%
0.8%